PepGen (PEPG) Projected to Post Earnings on Thursday

PepGen (NASDAQ:PEPG) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect PepGen to post earnings of ($0.31) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

PepGen (NASDAQ:PEPG) last announced its earnings results on Wednesday, March 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.13. On average, analysts expect PepGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PepGen Stock Down 4.4%

Shares of PEPG opened at $1.85 on Thursday. The company has a market cap of $127.62 million, a price-to-earnings ratio of -0.77 and a beta of 2.01. PepGen has a twelve month low of $1.01 and a twelve month high of $7.80. The company has a 50 day moving average of $3.62 and a two-hundred day moving average of $4.84.

Institutional Investors Weigh In On PepGen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of PepGen during the fourth quarter worth $638,000. Readystate Asset Management LP purchased a new position in shares of PepGen during the fourth quarter worth $739,000. Trexquant Investment LP purchased a new position in shares of PepGen during the fourth quarter worth $158,000. Jump Financial LLC purchased a new position in shares of PepGen during the fourth quarter worth $361,000. Finally, Laurion Capital Management LP raised its holdings in shares of PepGen by 8.5% during the fourth quarter. Laurion Capital Management LP now owns 2,052,133 shares of the company’s stock worth $13,359,000 after purchasing an additional 159,977 shares during the last quarter. 58.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Guggenheim lifted their price objective on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Wedbush lowered their price objective on shares of PepGen from $9.00 to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Oppenheimer assumed coverage on shares of PepGen in a research note on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a research note on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, PepGen has an average rating of “Moderate Buy” and an average target price of $11.80.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).